Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation

Inclusion Criteria: * End-stage renal disease awaiting transplantation on the UNOS list. * No known contraindications for therapy with IVIG10%/Rituximab, plasmapheresis (PLEX) or IdeS®. * Age 18-70 years at the time of screening. * Calculated PRA (CPRA)\> 50% demonstrated on 3 consecutive samples, Patient highly-HLA sensitized and a candidate for DD transplantation after desensitization at CSMC. * At transplant, patient must have donor-specific antibody/ crossmatch positive (DSA/CMX+) non-HLA identical donor. * Pre-transplant vaccination with Streptococcus pneumoniae and Nisseria meningitides * Subject/Parent/Guardian must be able to understand and provide informed consent. Exclusion Criteria: * Positivity for anti-IdeS IgE * Use of IVIG 4 weeks prior to planned IdeS® administration * Recipients of Extended Criteria Donors (ECD) or Living Donors (LD) * Lactating or pregnant females. * Women of child-bearing age who are not willing or able to practice FDA-approved forms of contraception. * HIV-positive subjects. * Subjects who test positive for HBV infection \[positive HBVsAg, HBVcAb, or HBVeAg/DNA\] or HCV infection \[positive Anti-HCV (EIA) and confirmatory HCV RIBA\]. * Subjects with active TB. * Subjects with selective IgA deficiency, those who have known anti-IgA antibodies, and those with a history of anaphylaxis or severe systemic responses to any part of the clinical trial material. * Subjects who have received or for whom multiple organ transplants are planned. * Recent recipients of any licensed or investigational live attenuated vaccine(s) within two months of the screening visit (including but not limited to any of the following: 1. Adenovirus \[Adenovirus vaccine live oral type 7\] 2. Varicella \[Varivax\] 3. Hepatitis A \[VAQTA\] 4. Rotavirus \[Rotashield\] 5. Yellow fever \[Y-F-Vax\] 6. Measles and mumps \[Measles and mumps virus vaccine live\] 7. Measles, mumps, and rubella vaccine \[M-M-R-II\] 8. Sabin oral polio vaccine 9. Rabies vaccines \[IMOVAX Rabies I.D., RabAvert\]) * A significantly abnormal general serum screening lab result defined as a WBC \< 3.0 X 103/ml, a Hgb \< 8.0 g/dL, a platelet count \< 100 X 103/ml, , an SGOT \> 3X upper limit . * Individuals deemed unable to comply with the protocol. * Subjects with active CMV or EBV infection as defined by CMV-specific serology (IgG or IgM) and confirmed by quantitative PCR with or without a compatible illness. * Subjects with a known history of previous myocardial infarction within one year of screening. * Subjects with a history of clinically significant thrombotic episodes, and subjects with active peripheral vascular disease. * Subjects with Protein C and Protein S deficiency * Use of investigational agents within 4 weeks of participation. * Known allergy/sensitivity to IdeS® infusions